Biotech & Pharma
Health Tech
Business & Policy
Health & Science
Team
Exclusive analysis of biotech, pharma, and the life sciences
Topics
Columns
Tools
Events
Team
Account
More
Follow Us
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
By Jonathan Wosen May 2, 2022
Bay Area biotech Guardant Health announced the commercial launch of its early-detection colon cancer test on Monday, marking the latest twist in an escalating race to spot cancer sooner and more accurately.
The company’s test, known as Shield, is available to adults 45 and older who aren’t up to date with current screening guidelines, don’t have symptoms, and are at average risk of colon cancer. Shield is a lab-developed test, meaning that it hasn’t been approved by the Food and Drug Administration and that each sample (about a tablespoon of blood) must be sent to Guardant’s lab.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
West Coast Biotech & Life Sciences Reporter
Jonathan Wosen is STAT’s West Coast Biotech & Life Sciences Reporter
cancer
STAT+
This name will appear with your comment
There was an error saving your display name. Please check and try again.
By Matthew Herper
By Adam Feuerstein and Damian Garde
advertisement
By Matthew Herper
By Matthew Herper
By Tino Delamerced
Reporting from the frontiers of health and medicine